Lixte Biotechnology raises $4.3M in registered direct offering; terminates royalty agreement

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Gross proceeds ~$4.3M from 1,051,342 Common Units at $4.09/unit; each unit includes one share (or Pre-Funded Warrant) and one Common Warrant (exercise $3.96, 60-month term).
Offering priced at market under Nasdaq rules; expected close Dec 19, 2025.
Terminated Royalty Agreement with Orbit Capital Inc. (dated Nov 24, 2025); both parties released from claims.
Net proceeds to be used for general corporate purposes and working capital.
Spartan Capital Securities acted as sole placement agent with 6% fee and $85K legal expense reimbursement.

item 1.01item 1.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.